🔎 Trials Near Me

Hjem › Melanom › Texas › Houston

Kliniske studier for Melanom i Houston, TX

59 studier for Melanom søker deltakere på steder i og rundt Houston (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

RekruttererFase 1
  • University of Texas MD Anderson Cancer Center, Houston
  • NEXT Houston, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06270706

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
  • UT MD Anderson Cancer Center, Houston
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

RekruttererFase 2
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06172478

A Study of BI 3810944 in Patients With Advanced Cancer

RekruttererFase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07224425

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

RekruttererFase 3
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06246916

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

RekruttererFase 2
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06548789

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

RekruttererFase 2
  • UT MD Anderson Cancer Center, Houston
Opp til 25 år · Alle kjønn · Oppdatert 24. sep. 2026 · NCT07621614

Pan-tumor MRD Study

RekruttererObservasjonsstudie
  • Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06605404

Intratumoral N17350 in Advanced Solid Tumors

RekruttererFase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07339176

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

RekruttererFase 1/2
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT05267626

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

RekruttererFase 1
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT04038619

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

RekruttererFase 2
  • Local Institution - 0085, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT07492680

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

RekruttererFase 1/2
  • University of Texas-MD Anderson, Houston
  • Lumi Research, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07287917

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

RekruttererFase 1
  • MD Anderson, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT04913285

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

RekruttererFase 1/2
  • The University of Texas M. D. Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT06683755

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

RekruttererFase 1
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT06545682

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RekruttererFase 1/2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
12 Months – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04851119

Project: Every Child for Younger Patients With Cancer

RekruttererObservasjonsstudie
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
Opp til 25 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT02402244

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

RekruttererObservasjonsstudie
  • M D Anderson Cancer Center, Houston
Alle aldre · Alle kjønn · Oppdatert 21. aug. 2026 · NCT01772771

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

RekruttererFase 1/2
  • Research Site, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT07115043

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

RekruttererFase 1/2
  • Houston Methodist Hospital, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT04895709

A Study of MGC026 in Participants With Advanced Solid Tumors

RekruttererFase 1
  • The University of Texas MD Anderson Cancer Center, Houston
  • University of Texas Health Science Center at Houston, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT06242470

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

RekruttererFase 1/2
  • The University of Texas, MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05592626

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

RekruttererFase 2
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 10. aug. 2026 · NCT04594187

IDOV-Immune for Advanced Solid Tumors

RekruttererFase 1
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06910657

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

RekruttererFase 1/2
  • M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 16. jul. 2026 · NCT06060613

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

RekruttererFase 2
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 16. jul. 2026 · NCT05704647

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

RekruttererFase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 12 til 50 · Alle kjønn · Oppdatert 15. jul. 2026 · NCT03093909

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

RekruttererFase 2
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 11. jun. 2026 · NCT04771520

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

RekruttererFase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 8. jun. 2026 · NCT03947385

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

RekruttererFase 1
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 1. jun. 2026 · NCT05039801

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

RekruttererFase 2
  • USA12-0, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT06953089

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Rekrutterer
  • M D Anderson Cancer Center, Houston
Alder 19 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT05053555

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

RekruttererObservasjonsstudie
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 20. mai 2026 · NCT04751396

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

RekruttererFase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 15. mai 2026 · NCT05379985

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

RekruttererFase 1/2
  • University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mai 2026 · NCT03686124

Neoadjuvant Darovasertib in Primary Uveal Melanoma

RekruttererFase 3
  • Retina Consultants of Texas - (Houston), Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT07015190

Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma

RekruttererObservasjonsstudie
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 5. mai 2026 · NCT04778449

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

RekruttererFase 1
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 20. apr. 2026 · NCT06326411

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

RekruttererFase 2
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 16. apr. 2026 · NCT05026983

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

RekruttererFase 1
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 16. apr. 2026 · NCT06660420

Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic

RekruttererObservasjonsstudie
  • M D Anderson Cancer Center, Houston
Alle aldre · Alle kjønn · Oppdatert 16. apr. 2026 · NCT04474301

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Rekrutterer
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 15. apr. 2026 · NCT04693377

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

RekruttererFase 1/2
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 13. apr. 2026 · NCT06362369

A Study of VET3-TGI in Patients With Solid Tumors

RekruttererFase 1
  • University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 7. apr. 2026 · NCT06444815

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

RekruttererFase 2/3
  • The University Of Texas Md Anderson Cancer Center, Houston
Alle aldre · Alle kjønn · Oppdatert 2. apr. 2026 · NCT06581406

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

RekruttererFase 3
  • Houston Methodist Hospital/Houston Methodist Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 25. feb. 2026 · NCT05549297

ACTengine® IMA203 Combined With mRNA-4203

RekruttererFase 1
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 8. jan. 2026 · NCT06946225

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

RekruttererFase 3
  • The University of Texas M.D. Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 17. des. 2025 · NCT03567889

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

RekruttererFase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 29. okt. 2025 · NCT06249048

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RekruttererObservasjonsstudie
  • Massive Bio SYNERGY-AI site, Houston
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

RekruttererFase 1/2
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 18. mai 2025 · NCT05970497

BostonGene and Exigent Genomic INsight Study

RekruttererObservasjonsstudie
  • Oncology Consultants, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 17. feb. 2025 · NCT06272864

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

RekruttererFase 1/2
  • Oncology Consultants, P.A., Houston
  • The University of Texas M. D. Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 13. feb. 2025 · NCT05669430

A Study of IBI363 in Subjects with Advanced Solid Malignancies

RekruttererFase 2
  • MD Anderson Cancer Center-University of Texas, Houston
  • Oncology Consultants P.A., Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 19. des. 2024 · NCT06281678

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Rekrutterer
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 27. nov. 2024 · NCT03860883

Melanom-studier i andre byer

Andre studier i Houston

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.